New-onset atrial fibrillation and acute coronary syndrome

Dennis H. Lau; Muayad Alasady; Anthony G. Brooks; Prashanthan Sanders

doi:10.1586/erc.10.61

New-onset atrial fibrillation and acute coronary syndrome

Dennis H. Lau, Muayad Alasady, Anthony G. Brooks, Prashanthan Sanders

Heart And Vascular Health

Research output: Contribution to journal › Review article › peer-review

36 Citations (Scopus)

Abstract

Despite advances in the diagnosis and management of acute coronary syndrome (ACS), atrial fibrillation (AF) remains a commonly encountered complication leading to adverse short- and long-term outcomes across the whole spectrum of ACS. At present, the underlying mechanisms of AF in myocardial ischemia remain incompletely understood. This article evaluates the incidence and trends of new-onset AF in ACS, its impact on ACS management and the associated prognostic significance in patients with acute ischemic heart disease. The safety and use of oral anticoagulation treatment in ACS patients on multiple antiplatelet agents are also explored. Further experimental and clinical studies are needed to improve current understanding and management of new-onset AF in ACS patients.

Original language	English
Pages (from-to)	941-948
Number of pages	8
Journal	Expert Review of Cardiovascular Therapy
Volume	8
Issue number	7
DOIs	https://doi.org/10.1586/erc.10.61
Publication status	Published or Issued - Jul 2010

Keywords

acute coronary syndrome
antiarrhythmic drugs
atrial fibrillation
oral anticoagulation

ASJC Scopus subject areas

Internal Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.1586/erc.10.61

Cite this

@article{e95289ba57534a0caaac445215817f91,

title = "New-onset atrial fibrillation and acute coronary syndrome",

abstract = "Despite advances in the diagnosis and management of acute coronary syndrome (ACS), atrial fibrillation (AF) remains a commonly encountered complication leading to adverse short- and long-term outcomes across the whole spectrum of ACS. At present, the underlying mechanisms of AF in myocardial ischemia remain incompletely understood. This article evaluates the incidence and trends of new-onset AF in ACS, its impact on ACS management and the associated prognostic significance in patients with acute ischemic heart disease. The safety and use of oral anticoagulation treatment in ACS patients on multiple antiplatelet agents are also explored. Further experimental and clinical studies are needed to improve current understanding and management of new-onset AF in ACS patients.",

keywords = "acute coronary syndrome, antiarrhythmic drugs, atrial fibrillation, oral anticoagulation",

author = "Lau, {Dennis H.} and Muayad Alasady and Brooks, {Anthony G.} and Prashanthan Sanders",

note = "Funding Information: Dennis H Lau is supported by a Medical Postgraduate Scholarship from the National Health and Medical Research Council of Australia, the Earl Bakken Electrophysiology Scholarship from the University of Adelaide, and a Biomedical Research Scholarship from Kidney Health Australia. Muayad Alasady is supported by a Divisional Scholarship and the Earl Bakken Electrophysiology Scholarship from the University of Adelaide, and a Medical Postgraduate Scholarship from the National Health and Medical Research Council of Australia. Anthony G Brooks and Prashanthan Sanders are supported by the National Heart Foundation of Australia. Prashanthan Sanders reports having served on the advisory board of and having received lecture fees and research funding from Bard Electrophysiology, Biosense-Webster, Medtronic and St. Jude Medical. The authors have no other relevant affiliations or financial involvement with",

year = "2010",

month = jul,

doi = "10.1586/erc.10.61",

language = "English",

volume = "8",

pages = "941--948",

journal = "Expert Review of Cardiovascular Therapy",

issn = "1477-9072",

publisher = "Taylor and Francis Ltd.",

number = "7",

}

TY - JOUR

T1 - New-onset atrial fibrillation and acute coronary syndrome

AU - Lau, Dennis H.

AU - Alasady, Muayad

AU - Brooks, Anthony G.

AU - Sanders, Prashanthan

N1 - Funding Information: Dennis H Lau is supported by a Medical Postgraduate Scholarship from the National Health and Medical Research Council of Australia, the Earl Bakken Electrophysiology Scholarship from the University of Adelaide, and a Biomedical Research Scholarship from Kidney Health Australia. Muayad Alasady is supported by a Divisional Scholarship and the Earl Bakken Electrophysiology Scholarship from the University of Adelaide, and a Medical Postgraduate Scholarship from the National Health and Medical Research Council of Australia. Anthony G Brooks and Prashanthan Sanders are supported by the National Heart Foundation of Australia. Prashanthan Sanders reports having served on the advisory board of and having received lecture fees and research funding from Bard Electrophysiology, Biosense-Webster, Medtronic and St. Jude Medical. The authors have no other relevant affiliations or financial involvement with

PY - 2010/7

Y1 - 2010/7

N2 - Despite advances in the diagnosis and management of acute coronary syndrome (ACS), atrial fibrillation (AF) remains a commonly encountered complication leading to adverse short- and long-term outcomes across the whole spectrum of ACS. At present, the underlying mechanisms of AF in myocardial ischemia remain incompletely understood. This article evaluates the incidence and trends of new-onset AF in ACS, its impact on ACS management and the associated prognostic significance in patients with acute ischemic heart disease. The safety and use of oral anticoagulation treatment in ACS patients on multiple antiplatelet agents are also explored. Further experimental and clinical studies are needed to improve current understanding and management of new-onset AF in ACS patients.

AB - Despite advances in the diagnosis and management of acute coronary syndrome (ACS), atrial fibrillation (AF) remains a commonly encountered complication leading to adverse short- and long-term outcomes across the whole spectrum of ACS. At present, the underlying mechanisms of AF in myocardial ischemia remain incompletely understood. This article evaluates the incidence and trends of new-onset AF in ACS, its impact on ACS management and the associated prognostic significance in patients with acute ischemic heart disease. The safety and use of oral anticoagulation treatment in ACS patients on multiple antiplatelet agents are also explored. Further experimental and clinical studies are needed to improve current understanding and management of new-onset AF in ACS patients.

KW - acute coronary syndrome

KW - antiarrhythmic drugs

KW - atrial fibrillation

KW - oral anticoagulation

UR - http://www.scopus.com/inward/record.url?scp=77954516058&partnerID=8YFLogxK

U2 - 10.1586/erc.10.61

DO - 10.1586/erc.10.61

M3 - Review article

C2 - 20602555

AN - SCOPUS:77954516058

SN - 1477-9072

VL - 8

SP - 941

EP - 948

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

IS - 7

ER -

New-onset atrial fibrillation and acute coronary syndrome

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this